Literature DB >> 7203959

Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate.

E Varenhorst, B Risberg.   

Abstract

Twenty-six patients with carcinoma of the prostate were allocated to treatment by subcapsular orchidectomy, estrogen administration, or cyproterone acetate administration. Tissue fibrinolytic activity in skin biopsy specimens was estimated by a histochemical method before treatment was initiated and 2 and 8 weeks later. Orchidectomy caused no significant changes in the fibrinolytic activity. During estrogen therapy the fibrinolytic activity in skin was significantly reduced at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. In the group given cyproterone acetate the activity was significantly increased at 8 weeks. The reduction in fibrinolytic activity in skin could contribute to the increased risk of thromboembolism during estrogen treatment of patients with cancer of the prostate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7203959

Source DB:  PubMed          Journal:  Invest Urol        ISSN: 0021-0005


  3 in total

1.  Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.

Authors:  Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg
Journal:  Lancet Oncol       Date:  2010-04-13       Impact factor: 41.316

2.  Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.

Authors:  J E Damber; L Daehlin; R Tomic; T K Nilsson
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

Review 3.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.